Protective effect of the heparin-derived oligosaccharide C3, on AF64A-induced cholinergic lesion in rats

Neurobiology of Aging

Volumn 24, Issue 3, 2003, Pages 481-490

  Rose, M ^a   Dudas, B ^a   Cornelli, U ^a   Hanin, I ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

AF64A; C3; Cholinergic lesion; Cingulum bundle; Glycosaminoglycan; Heparin derived oligosaccharide; Septum

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; ETHYLCHOLINE MUSTARD AZIRIDINIUM; HEPARIN DERIVATIVE; HEPARIN DERIVED OLIGOSACCHARIDE; OLIGOSACCHARIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN TOXICITY; CELL COUNT; CHOLINERGIC ACTIVITY; CINGULATE GYRUS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LATERAL BRAIN VENTRICLE; MALE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SEPTUM PELLUCIDUM; STEREOTAXIC SURGERY;

ACETYLCHOLINESTERASE; ANIMALS; AZIRIDINES; BRAIN CHEMISTRY; CELL COUNT; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DRUG INTERACTIONS; GLYCOSAMINOGLYCANS; GYRUS CINGULI; HEPARIN; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OLIGOSACCHARIDES; RATS; RATS, INBRED F344; SEPTUM OF BRAIN;

EID: 0037405986     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00093-3     Document Type: Article

References (63)

1. Bartus R.T. Physostigmine and recent memory: effects in young and aged nonhuman primates. Science. 206:1979;1087-1089.
2. Beatty W.W., Carbone C.P. Septal lesions, intramaze cues and spatial behavior in rats. Physiol. Behav. 24:1980;675-678.
3. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M.et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci. 22:2002;3234-3243.
4. Castillo G.M., Ngo C., Cummings J., Wight T.N., Snow A.D. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 69:1997;2452-2465.
5. Chrobak J., Hanin I., Walsh T. AF64A (ethylcholine aziridinium ion), a cholinergic neurotoxin, selectively impairs working memory in a multiple component T-maze task. Brain Res. 414:1987;15-21.
6. Chrobak J., Hanin I., Schmechel D.E., Walsh T.J. AF64A-induced working memory impairment: behavioral, neurochemical and histological correlates. Brain Res. 463:1988;107-117.
7. Conti L., Re F., Lazzerini F., Morey L.C., Ban T.A., Santini V.et al. Glycosaminoglycan polysulfate (Ateroid) in old-age dementias: effects upon depressive symptomatology in geriatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 13:1989;977-981.
8. Conti L., Placidi G.F., Cassano G.B. Ateroid in the treatment of dementia: results of a clinical trial. Mod. Probl. Pharmacopsychiatry. 23:1989;76-84.
9. Cornelli U. The therapeutic approach to Alzheimer's disease. In: Haremberg J, Casu B, editors. Non-anticoagulant action of glycosaminoglycans. New York, NY: Plenum Press, 1996. p. 249-79.
10. Damon D., D'Amore P., Wagner J. Sulfated glycosaminoglycans modify growth factor-induced neurite outgrowth in PC12 cells. J. Cell. Physiol. 135:1988;293-300.
11. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;403.
12. Davis K.L., Mohs R.C., Tinklenberg J.R., Pfefferbaum A., Hollister L.E., Kopell B.S. Physostigmine: improvement of long-term memory processes in normal humans. Science. 201:1978;272-274.
13. Dong X.W., Hanin I., Lorens S.A. AF64A affects septal choline acetyltransferase but not parvalbumin immunoreactive cells. Brain Res. Bull. 35:1994;217-220.
14. Dudas B., Cornelli U., Lee J.M., Hejna M.J., Walzer M., Lorens S.A.et al. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Aβ(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol. Aging. 23:2002;97-104.
15. El Tamer A., Corey J., Wülfert E., Hanin I. Reversible cholinergic changes induced by AF64A in rat hippocampus and possible septal compensatory effect. Neuropharmacology. 31:1992;397-402.
16. Fan Q., Hanin I. Effects of AF64A on gene expression of choline acetyltransferase (ChAT) in the septo-hippocampal pathway and striatum in vivo. Neurochem. Res. 24:1999;15-24.
17. Fisher A, Pittel Z, Haring R, Brandeis R, Bar-Ner N, Sonego H, et al. In: Mizuno Y, Fisher A, Hanin I, editors. Mapping the progress of Alzheimer's and Parkinson's disease. New York: Academic/Plenum Press, 2002. p. 205-10.
18. Fisher A., Hanin I. Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Annu. Rev. Pharmacol. Toxicol. 26:1986;161-181.
19. Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 115:1969;465-472.
20. Gau J.T., Steinhilb M.L., Kao T.C., D'Amato C.J., Gaut J.R., Frey K.A.et al. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. 160:2002;731-738.
21. Glenner G.G., Wong C.W., Quaranta V., Eanes E.D. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl. Pathol. 2:1984;357-369.
22. Glick S.D., Mittag T.W., Green J.P. Cental cholinergic correlates of impaired learning. Neuropharmacology. 12:1973;291-296.
23. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science. 293:2001;1491-1495.
24. Gupta-Bansal R., Frederickson C.A., Brunden K.R. Proteoglycan-mediated inhibition of Aβ proteolysis. J. Biol. Chem. 270:1995;18666-18671.
25. Hanin I. The centrally cholino-deficient animal as a model of Alzheimer's disease (AD). In: Giacobini E, Becker R, editors. Alzheimer's disease: therapeutic strategies. Boston: Birkhauser, 1994. p. 367-74.
26. Hanin I. The AF64A model of cholinergic hypofunction: an update. Life Sci. 58:1996;1955-1964.
27. Hefti F., Dravid A., Hartikka J. Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase in adult rats with partial septo-hippocampal lesions. Brain Res. 293:1984;305-311.
28. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:1995;143-148.
29. Ksiezak-Reding H., Liu W.K., Yen S.H. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597:1992;209-219.
30. Lesma E., Di Giulio A.M., Ferro L., Prino G., Gorio A. Glycosaminoglycans in nerve injury: I. Low doses of glycosaminoglycans promote neurite formation. J. Neurosci. Res. 46:1996;565-571.
31. Leventer S., McKeag D., Clancy M., Wülfert E., Hanin I. Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices. Neuropharmacology. 24:1985;453-459.
32. Leveugle B., Scanameo A., Ding W., Fillit H. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport. 5:1994;1389-1392.
33. Lim D.K., Oh Y.H., Kim H.S. Impairments of learning and memory following intracerebroventricular administration of AF64A in rats. Arch. Pharm. Res. 24:2001;234-239.
34. Lorens S.A., Kindel G., Dong X.W., Lee J.M., Hanin I. Septal choline acetyltransferase immunoreactive neurons: dose-dependent effects of AF64A. Brain Res. Bull. 26:1991;965-971.
35. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12243-12247.
36. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:1951;265-267.
37. Lucas C., Czlonkowska A., Kreutzberg G. Regulation of acetylcholinesterase by nerve growth factor in the pheochromocytoma PC12 cell line. Neurosci. Lett. 18:1980;333-337.
38. Ma Q., Dudas B., Hejna M., Cornelli U., Lee J.M., Lorens S.et al. The blood-brain barrier accessibility of a heparin-derived oligosaccharide C3. Thromb. Res. 105:2002;447-453.
39. Ma Q., Dudas B., Daud A., Iqbal O., Hoppensteadt D., Jeske W.et al. Molecular and biochemical profiling of a heparin derived oligosaccharide, C3. Thromb. Res. 105:2002;303-309.
40. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4245-4249.
41. Mervis R., McKean J., Zats S., Gum A., Reinhart R., Dudas B.et al. Neurotrophic effects of the glycosaminoglycan C3 on dendritic arborization and spines in the adult rat hippocampus: a quantitative Golgi study. CNS Drug Rev. 6:2000;44-46.
42. 3H ]acetylcholine synthesis after AF64A-treatment in primary, neuron-enriched, rat septal-hippocampal and striatal cultures Brain Res. 42:1993;113-118.
43. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K.et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301:1993;41-52.
44. Mouton P.R., Arendash G.W. Atrophy of cholinergic neurons within the rat nucleus basalis magnocellularis following intracortical AF64A infusion. Neurosci. Lett. 111:1990;52-57.
45. Nitsch R.M., Deng M., Tennis M., Schoenfeld D., Growdon J.H. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 48:2000;913-918.
46. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
47. Passeri M., Cucinotta D. Ateroid in the clinical treatment of multi-infarct dementia. Mod. Probl. Pharmacopsychiatry. 23:1989;85-94.
48. Potter P.E., Tedford C.E., Kindel G., Hanin I. Inhibition of high affinity choline transport attenuates both cholinergic and non-cholinergic effects of ethylcholine aziridinium (AF64A). Brain Res. 487:1989;238-244.
49. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. London: Academic Press, 1986.
50. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B.et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270:1995;9564-9570.
51. Roher A.E., Lowenson J.D., Clarke S., Wolkow C., Wang R., Cotter R.J.et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268:1993;3072-3083.
52. Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J., Gowing E.et al. Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10836-10840.
53. Roher A.E., Palmer K.C., Yurewicz E.C., Ball M.J., Greenberg B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J. Neurochem. 61:1993;1916-1926.
54. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17:1996;893-901.
55. Shaffer L.M., Dority M.D., Gupta-Bansal R., Frederickson R.C., Younkin S.G., Brunden K.R. Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol. Aging. 16:1995;737-745.
56. Snow A.D., Sekiguchi R.T., Nochlin D., Kalaria R.N., Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol. 144:1994;337-347.
57. Snow A.D., Kinsella M.G., Parks E., Sekiguchi R.T., Miller J.D., Kimata K.et al. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320:1995;84-95.
58. Swanson LW. Brain maps: structure of the rat brain. 2nd ed. Amsterdam, The Netherlands: Elsevier, 1998.
59. Tedford CE, Lorens SA, Corey JC, Lokhorst D, Kindel G, Wülfert E, et al. Behavioral and neurochemical effects of AF64A in young and old Fisher 344 male rats. In: Nagatsu T, Fisher A, Yoshida M, editors. Basic, clinical, and therapeutic aspects of Alzheimer's disease and Parkinson's disease. New York: Plenum Press, 1990. p. 321-34.
60. Tran M.H., Yamada K., Nabeshima T. Molecular mechanisms of cholinergic dysfunction and cognitive deficits induced by amyloid beta-peptide. Nihon Shinkei Seishin Yakurigaku Zasshi. 21:2001;125-132.
61. Walicke P. Interactions between basic fibroblast growth factor (FGF) and glycosaminoglycans in promoting neurite outgrowth. Exp. Neurol. 102:1988;144-148.
62. Walzer M., Lorens S., Henja M., Fareed J., Hanin I., Cornelli U.et al. Low molecular weight glycosaminoglycan blockade of beta amyloid induced neuropathology. Eur. J. Pharmacol. 445(3):2002;211-220.
63. Wischik C.M., Novak M., Thogersen H.C., Edwards P.C., Runswick M.J., Jakes R.et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 85:1988;4506-4510.